Rockefeller Capital Management
LAB icon

Rockefeller Capital Management’s Standard BioTools LAB Stock Holding History

Rockefeller Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$353K Sell
428,510
-98,898
-19% -$93.4K ﹤0.01% 2273
2026
Q1 		$485K Buy
527,408
+83,264
+19% +$101K ﹤0.01% 1996
2025
Q4 		$569K Buy
444,144
+112,920
+34% +$152K ﹤0.01% 1834
2025
Q3 		$431K Sell
331,224
-10,000
-3% -$13.1K ﹤0.01% 1840
2025
Q2 		$409K Buy
341,224
+16,544
+5% +$18.3K ﹤0.01% 1601
2025
Q1 		$351K Buy
324,680
+28,049
+9% +$39.4K ﹤0.01% 1568
2024
Q4 		$519K Buy
296,631
+135,075
+84% +$252K ﹤0.01% 1462
2024
Q3 		$312K Buy
161,556
+1,000
+0.6% +$1.96K ﹤0.01% 1536
2024
Q2 		$284K Buy
160,556
+890
+0.6% +$2.17K ﹤0.01% 1557
2024
Q1 		$433K Buy
159,666
+29,023
+22% +$70.1K ﹤0.01% 1514
2023
Q4 		$289K Sell
130,643
-1,125
-0.9% -$2.4K ﹤0.01% 1472
2023
Q3 		$382K Buy
131,768
+728
+0.6% +$1.9K ﹤0.01% 1365
2023
Q2 		$253K Sell
131,040
-3,000
-2% -$5.92K ﹤0.01% 1573
2023
Q1 		$261K Hold
134,040
– – ﹤0.01% 1667
2022
Q4 		$156K Sell
134,040
-17,000
-11% -$20.9K ﹤0.01% 1789
2022
Q3 		$166K Buy
151,040
+33,000
+28% +$49.9K ﹤0.01% 1729
2022
Q2 		$188K Buy
118,040
+5,000
+4% +$12.4K ﹤0.01% 1662
2022
Q1 		$405K Buy
113,040
+113,030
+1,130,300% +$390K ﹤0.01% 1399
2021
Q4 		$0 Hold
10
– – ﹤0.01% 3887
2021
Q3 		$0 Hold
10
– – ﹤0.01% 3768
2021
Q2 		$0 Buy
+10
New +$53 ﹤0.01% 3525
2021
Q1 		– Sell
-5,715
Closed -$34K – 3329
2020
Q4 		$34K Buy
+5,715
New +$37.5K ﹤0.01% 1810

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Rockefeller Capital Management's LAB Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Standard BioTools (LAB) stake by 19% in Q2 2026, selling an estimated $93.4K and leaving 428,510 shares worth $353K. The position accounts for ﹤0.01% of the portfolio, ranked #2273.

Rockefeller Capital Management first reported a position in LAB in Q4 2020 and has held it in 22 quarters since. The position peaked at $569K in Q4 2025. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Rockefeller Capital Management held 428,510 shares of Standard BioTools worth $353K as of Q2 2026.
  • Rockefeller Capital Management sold 98,898 Standard BioTools shares in Q2 2026, an estimated $93.4K.
  • Standard BioTools made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2273 holding.
  • Rockefeller Capital Management first reported a position in Standard BioTools in Q4 2020 and has held it in 22 quarters since.
  • Rockefeller Capital Management's Standard BioTools position peaked at $569K in Q4 2025.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.